Vertex is running a phase 2 trial of inaxaplin in APOL1-mediated kidney diseases, including some forms of FSGS. The phase 3 ...

By placing the cells on surfaces patterned with fractal shapes that mimic natural structures in the kidney, the team ...

In a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 ...

The start-up Function will send practically anyone to a lab for extensive medical testing, no physical required. Is that a good thing? By Kristen V. Brown As Kimberly Crisp approached middle age, ...

Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental ...

Boehringer Ingelheim has reported encouraging Phase II trial results for apecotrep (BI 764198), a potential first-in-class oral TRPC6 inhibitor being developed for primary focal segmental ...

Shares of Travere Therapeutics TVTX were down 14.6% on Tuesday after the company announced that the FDA had extended the review timeline for the supplemental new drug application (sNDA) seeking label ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with prima ...

Sherri Gordon, CLC is a certified professional life coach, author, and journalist covering health and wellness, social issues, parenting, and mental health. She also has a certificate of completion ...